CSF2 and neoplasm: Receiving an injection of GVAX, a vaccine which was developed by combining autologous tumor cells with an allogeneic cell line that secretes GM-CSF, resulted in enhanced survival rates for patients with metastatic NSCLC who had previously experienced chemotherapy failure.